Evaluating the cost-effectiveness of clinical and public health measures

Annual Review of Public Health

Volumn 19, Issue , 1998, Pages 125-152

  Graham, John D ^a   Corso, Phaedra S ^a,b   Morris, Jill M ^a   Segui Gomez, Maria ^a   Weinstein, Milton C ^a  

^a HARVARD CENTER FOR RISK ANALYSIS   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cancer; Cost effectiveness; Heart disease; Infectious disease; Trauma

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOROURACIL; METHOTREXATE; MEVINOLIN; NAVELBINE; SIMVASTATIN; STREPTOKINASE; TAMOXIFEN;

CANCER SCREENING; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; OCCULT BLOOD; PAPANICOLAOU TEST; PRIORITY JOURNAL; PUBLIC HEALTH; RESOURCE ALLOCATION; REVIEW; UTERINE CERVIX CANCER;

COMMUNICABLE DISEASE CONTROL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HEALTH SERVICES RESEARCH; HUMANS; NEOPLASMS; PUBLIC HEALTH; UNITED STATES; WOUNDS AND INJURIES;

EID: 0031866909     PISSN: 01637525     EISSN: None     Source Type: Journal    
DOI: 10.1146/annurev.publhealth.19.1.125     Document Type: Review

References (19)

1. AuBuchon JP, Birkmeyer JD. 1994. Safety and cost-effectiveness of solvent-detergent-treated plasma: in search of a zero-risk blood supply. JAMA 272:1210-14
2. Birkmeyer JD, AuBuchon JP, Litenberg B, O'Connor GT, Nease RF, et al. 1994. Cost-effectiveness of preoperative autologous donation in coronary artery bypass surgery. Ann. Thorac. Surg. 57:161-69
3. Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsu PG, Littenberg B. 1993. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 33:544-51
4. Blincoe LJ. 1996. The Economic Cost of Motor Vehicle Crashes, 1994. Washington, DC: Natl. Traffic Saf. Admin., US Dep. Transport.
5. Bloom BS, Hillinan AL, Fendrisk AM, Schwartz JS. 1993. A reappraisal of Hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann. Intern. Med. 118:298-306
6. Brasel KJ, Weigelt JA. 1996.Blunt thoracic aortic trauma. A cost-utility approach for injury detection. Arch. Surg. 131:619-25; discussion 625-26
7. Busch MP, Korelitz JJ, Kleinman SH, Lee SR, AuBuchon JP, Schreiber GB. 1995. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion Hepatitis B and C virus infection. Transfusion 35:903-10
8. Cameron ID, Lyle DM, Quine S. 1994. Cost effectiveness of accelerated rehabilitation after proximal femoral fracture. J. Clin. Epidemiol. 47:1307-13
9. Centers for Disease Control and Prevention, [online]. 1997. http://www.cdc.gov
10. Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths, prevalence - United States, 1996. Morbid. Mortal. Wkly. Rev. 46(8):165-172
11. Chavey WE, Cantor SB, Clover RD, Reinarz JA, Spann SJ. 1994. Cost-effectiveness analysis of screening health care workers for HIV. J. Fam. Pract. 38:249-57
12. Drummond M, Stoddart G. 1995. Assessment of health producing measures across different sectors. Health Policy 33:219-31
13. Drummond M, Torrance G, Mason J. 1993. Cost-effectiveness league tables: more harm than good? Soc. Sci. Med. 31:33-40
14. Eddy DM. 1989. Screening for breast cancer. Ann. Intern. Med. 111:389-99
15. Eddy DM. 1990. Screening for cervical cancer. Ann. Intern. Med. 113:214-26
16. Eddy DM. 1990. Screening for colorectal cancer. Ann. Intern. Med. 113:373-84
17. Edleson JT, Weinstein MC, Tosteson A, Williams L, Lee TH, Goldman L. 1990. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 263:408-13
18. Fahs MC, Mandelblatt M, Schechter C, Muller C. 1992. Cost effectiveness of cervical cancer screening for the elderly. Ann. Intern. Med. 117:520-27
19. Francis RM, Anderson FH, Torgerson DJ. 1995. A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br. J. Rheumatol. 34:1167-71